Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Antidepressants vs placebo

Acceptability ‐ total dropouts · adults with cancer and depression

It is very uncertain whether antidepressants changes dropouts due to any cause (acceptability) compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.85 [0.52, 1.38]
9 studies · 479 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low

Mirtazapine vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · adults with cancer and depression

It is very uncertain whether mirtazapine changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.65 [0.2, 2.15]
1 study · 33 participants
Very low